RxDoctor Payments Data

Megan Bradshaw

Family · Greenfield, INNPI 1376901405

Payments from drug & device makers

$10,592in general payments, 2019–2025

Across 543 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$829
  • Sanofi$630
  • Grifols USA, LLC$610
  • Amgen$511
  • plus $5K from 41 others

What the payments were for

  • Food & beverage$10,32898%
  • Education$2652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,592 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$44,526
Medicare patients
237
Services billed
606

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$257,713
Trelegy ElliptaFluticasone/Umeclidin/Vilanter213$227,002
OfevNintedanib Esylate14$184,808
Dupixent PenDupilumab44$164,412
Breztri AerosphereBudesonide/Glycopyr/Formoterol150$116,437
Dupixent SyringeDupilumab14$53,210
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$36,483
Spiriva RespimatTiotropium Bromide43$36,036
Combivent RespimatIpratropium/Albuterol Sulfate15$9,204
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,168
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$5,842
AbrysvoRsv Vacc, Pref A And Pref B/Pf17$5,463
Albuterol Sulfate HfaAlbuterol Sulfate233$5,433
SymbicortBudesonide/Formoterol Fumarate12$4,146
Ventolin HfaAlbuterol Sulfate34$2,848

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$388$266,531128 claims
Grifols USA, LLCProlastin C$610$257,71313 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,058$234,170228 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,873$120,583162 claims
PfizerAbrysvo$79$5,46317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Greenfield

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →